KRAS and neoplasm: In a metastatic model, however, the combination reduced tumor size and PCNA staining more than either monotherapy.<h4>Conclusions</h4>Our results suggest that targeting polyamine metabolism with SAM486A enhances the efficacy of KRAS<sup>G12C</sup> inhibitors and may mitigate resistance.